Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177

Benzinga Newsdesk www.benzinga.com Negative 89.0%

Neg 89% Neu 0% Pos 0%

Morgan Stanley analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $179 to $177.